Investigational drug · Phase 2
Valaciclovir
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
144
Any phase or sponsor naming "Valaciclovir"
First trial start
2026
Apr 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Valaciclovir", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma (GBM)
- High Grade Gliomas
- Recurrent Glioblastoma
- Newly Diagnosed Glioblastoma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Valaciclovir" as an intervention, largest first.
- A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001038 · 1,200 participants · Primary completion May 1996
Drug: Valacyclovir hydrochloride; Acyclovir · For: Cytomegalovirus Infections; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 35 sites in all
- Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital HerpesPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00306787 · 1,179 participants · Start Mar 2006 · Primary completion Feb 2008
Drug: Famciclovir; Valacyclovir and 2 more · For: Genital Herpes
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 66 sites in all
- A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's PalsyPivotal-lookingCompleted
Wenzhou Medical UniversityAcademic, hospital or other
NCT01686464 · 882 participants · Start Jun 1998 · Primary completion Jan 2005
Drug: prednisone and valacyclovir treatments · For: Bell's Palsy
Sites: Xi’an, China
- Scandinavian Bell's Palsy StudyPivotal-lookingCompleted
Uppsala University HospitalAcademic, hospital or other
NCT00510263 · 839 participants · Start May 2001 · Primary completion Sep 2007
Drug: Prednisolone + placebo; Valaciclovir + placebo and 2 more · For: Bell's Palsy
- Phase III Study of ASP2151 in Herpes Zoster PatientsPivotal-lookingCompleted
Maruho Co., Ltd.Industry
NCT01959841 · 751 participants · Start Aug 2013 · Primary completion Jul 2015
Drug: ASP2151; valaciclovir · For: Herpes Zoster
Sites: Sapporo, Japan; Yokohama, Japan; Nakano-Ku, Japan
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerPivotal-lookingActive, not recruiting
Candel Therapeutics, Inc.Industry
NCT01436968 · 711 participants (planned) · Start Sep 2011 · Primary completion Aug 2024
Drug: Aglatimagene besadenovec + valacyclovir; Placebo + valacyclovir · For: Prostate Cancer
Sites: Gilbert, Arizona; Glendale, Arizona; Peoria, Arizona · 73 sites in all
- A Study With ASP2151 in Subjects With Recurrent Episodes of Genital HerpesPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00486200 · 695 participants · Start Jun 21, 2007 · Primary completion Aug 12, 2008
Drug: ASP2151; valacyclovir and 1 more · For: Herpes Genitalis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 25 sites in all
- Zoster Eye Disease StudyPivotal-lookingCompleted
NYU Langone HealthAcademic, hospital or other
NCT03134196 · 527 participants · Start Aug 23, 2017 · Primary completion Dec 31, 2023
Drug: Masked Placebo; Masked Oral Valacyclovir · For: Herpes Zoster Ophthalmicus
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 78 sites in all
- Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)Pivotal-lookingRecruiting
Candel Therapeutics, Inc.Industry
NCT07660094 · 500 participants (planned) · Start Jun 15, 2026 · Primary completion Oct 22, 2031
Drug: Aglatimagene Besadenovec; Valacyclovir and 2 more · For: Non-squamous, Non-Small Cell Lung Cancer
Sites: New York, New York
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
Newest research
PubMed records naming it or its code names, newest first.
- Early first-trimester CMV screening in a regional perinatal network: a multicenter descriptive study.
Collin-Bund V, Pierrat M, Zilliox M, et al. · J Matern Fetal Neonatal Med 2026
- Improvement of pregnancy outcome following primary CMV infection after the introduction of valacyclovir in the clinical practice in Italy, updated data from a large real-life multicenter study.
Zammarchi L, Beltrami A, Liuzzi G, et al. · Am J Obstet Gynecol MFM 2026
- Current Practices in Antenatal CMV Testing and Management in Belgium.
Costa E, Jong CP, Verleye L, et al. · Prenat Diagn 2026
- Acute retinal necrosis refractory to treatment.
Reekie IR, Sidhom J, Chavan R · BMJ Case Rep 2026
- Interventions for treatment of herpes labialis (cold sores on the lips).
Lin HS, Lin PT, Shih IC, et al. · Cochrane Database Syst Rev 2026
- ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand.
Henden A, Chee L, Clark J, et al. · Intern Med J 2026
Also in development for Glioblastoma (GBM)
- BreakVaxPhase 22 trials
BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)
- DOC1021Phase 22 trials
Diakonos Oncology Corporation · Glioblastoma (GBM), Refractory Melanoma
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
- silevertinibBDTX-1535Phase 22 trials
Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM
- JBI-778Phase 21 trial
Jubilant Therapeutics Inc. · Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG)
- TGX-007Phase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.